Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

13.94
BATS BZX Real-Time Price
As of 2:09pm ET
 -0.79 / -5.40%
Today’s Change
13.00
Today|||52-Week Range
101.40
-4.03%
Year-to-Date
A Fond Farewell
Jan 21 / GuruFocus News - Paid Partner Content
Valeant Pharmaceuticals: Separating Fact From Fiction
Jan 11 / MotleyFool.com - Paid Partner Content
Short-Seller Andrew Left Says Trump Should Target This Aerospace Stock
Jan 20 / TheStreet.com - Paid Partner Content
Trump: Drug companies 'getting away with murder'
Jan 11 / CNNMoney.com
What Will Valeant Pharmaceuticals Sell Off Next?
Jan 20 / MotleyFool.com - Paid Partner Content
Do Options Traders Know Something About Valeant Pharmaceuticals (VRX) Stock We Don't?...
Jan 11 / Zacks.com - Paid Partner Content
Why TransDigm Stock Tumbled 12% Today
Jan 20 / MotleyFool.com - Paid Partner Content
This Is the Smartest Move Valeant Pharmaceuticals Has Made in a Really Long Time
Jan 11 / MotleyFool.com - Paid Partner Content
Frontrunning: January 18
Jan 18 / Investing Channel - Paid Partner Content
Will This Cure What Ails Valeant Pharmaceuticals?
Jan 10 / MotleyFool.com - Paid Partner Content
Will This Be a Genius or Foolish Move for Johnson & Johnson?
Jan 13 / MotleyFool.com - Paid Partner Content
Why Valeant Pharmaceuticals Stock Is Jumping Today
Jan 10 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News
Jan 13 / Zacks.com - Paid Partner Content
Valeant to Sell Dendreon Unit to Sanpower for $820 Million
Jan 10 / Zacks.com - Paid Partner Content
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
Jan 12 / Zacks.com - Paid Partner Content
3 Tempting Stocks We're Avoiding
Jan 10 / MotleyFool.com - Paid Partner Content
Valeant Streamlines Portfolio with Skincare Brands Sale
Jan 11 / Zacks.com - Paid Partner Content
Top Biotech Resolutions for 2017
Jan 09 / MotleyFool.com - Paid Partner Content